Conscious Sedation Clinical Trial
Official title:
A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department
Verified date | April 2022 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this project is to compare the sedative effects of intranasal midazolam versus inhaled nitrous oxide (N2O) for minor procedures in the pediatric emergency department. The primary outcome will be length of stay (LOS) in the emergency department (ED) stay for minor procedures. Secondarily the investigators will compare patient/family and provider satisfaction while using either intranasal midazolam or N2O for minimal sedation. The investigators hypothesize that the total length of stay for children undergoing minor procedures in the ED will be lower for N2O, as compared to intranasal midazolam. The investigators also hypothesize that patient/family and provider satisfaction will be higher with N2O and adverse effects will not differ between N2O and intranasal midazolam. Patients will receive either intranasal midazolam or N2O for minor procedures. Following the enrollment period, data will be analyzed and the two will be compared. Total length of stay, patient/family and provider satisfaction will be studied.
Status | Completed |
Enrollment | 63 |
Est. completion date | November 8, 2018 |
Est. primary completion date | November 8, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility | Inclusion Criteria: 1. Patients =2 years of age and <18 years of age, and 2. Parent/legal guardian age =18 years of age to <80 years of age 3. Patients with an American Society of Anesthesiologists (ASA) Physical Status Classification System level 1, 2, and 3 4. Patients requiring anxiolysis and mild sedation for minor procedures 1. Minor procedures will include simple lacerations less than 4 cm 2. Lumbar punctures 3. Minor incision 4. Drainage of abscesses that do not require extensive debridement 5. Must receive the standard of care dosing for either nitrous oxide or intranasal midazolam. 1. Nitrous oxide up to 70% nitrous concentration will be allowed 2. Intranasal Midazolam 0.4mg/kg with a max dose of 10mg Exclusion Criteria: 1. Nasal injury, nasal obstruction or significant congestion 2. Laceration that involves the nose and ears or come into contact with the scavenger device or nitrous oxide tubing 3. Allergy to benzodiazepines 4. Benzodiazepine dosing for any reason 24 hours prior to procedure 5. Excessive Epistaxis 6. Facial or nasal deformity 7. Copious mucous 8. Recent (less than 1 week) tympanic membrane graft or middle ear surgery 9. Recent bleomycin therapy 10. Patients known to be pregnant at time of enrollment 11. Patients with severe behavior problems, personality disorders or other mind-altering conditions as determined by administering provider. 12. Closed space situations such as: 1. pneumothorax, 2. air embolus, 3. pneumocephalus, or 4. craniotomy in the last 3 weeks, 5. intraocular surgery with retained gas, 6. pulmonary bullae, 7. severe emphysema, or 8. bowel obstruction. 13. Patients with significant co-morbidities: 1. severe pulmonary disease, 2. cardiac disease, 3. hematologic diseases associated with B12 deficiency, 4. sickle cell disease. 14. Patients with acute otitis media and/or sinusitis 15. History of paradoxical reaction to nitrous oxide 16. Known Methicillin-resistant Staphylococcus aureus (MRSA+) patients 17. Co-administration of additional sedation or analgesic medications |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Colorado | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ED Length of Stay After Intranasal Midazolam or Nitrous Oxide Administration | The total length of Emergency Department (ED) stay will be defined as time from intranasal midazolam or nitrous oxide administration to time of discharge readiness, collected by the research assistants. Additional time periods measured will include: time from anxiolytic/sedative given to time of procedure completion, and total time for recovery. | From administration of intranasal midazolam or nitrous oxide, assessed over an estimated time of 2 hours. | |
Secondary | Patient/Parent and Provider Satisfaction With Sedation and Anxiolytic/Sedative. | Patient/parent satisfaction will be assessed for all patients; child satisfaction will be assessed for patients over 12 years of age. Satisfaction will be measured on a scale of 1 to 5 (1 being not satisfied and 5 being very satisfied). Specifically, parents (and children when applicable) will be asked "how satisfied with the means of sedation were you for the procedure performed". Research assistants will then ask the ED providers on a scale of 1 to 5 (1 being not satisfied and 5 being very satisfied) "how satisfied with the means of sedation were you for the procedure performed". | Time of discharge, Approximately 2 hours | |
Secondary | Adverse Events. | Number of adverse events observed. Adverse events will be classified and defined as hypoxia, need for administration of reversal agent, nausea, vomiting, paradoxical reaction, airway obstruction, laryngospasm, inadequate sedation, allergic reaction, and cardiac arrest. | Time of discharge, Approximately 2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02573818 -
Sedasys Post Approval Study Users Response to System Alarms
|
N/A | |
Recruiting |
NCT01100554 -
Upper Airway Collapsibility Evaluation in Different Sedative Levels by Sleep Endoscopy
|
N/A | |
Terminated |
NCT00226785 -
Dexmedetomidine for Continuous Sedation
|
Phase 3 | |
Completed |
NCT02518919 -
Procedural Sedation And Analgesia in Children in the Emergency Department: The Role of Adjunct Therapies
|
N/A | |
Enrolling by invitation |
NCT04172415 -
Current Procedural Sedation Practices in a Canadian Community Emergency Department
|
||
Completed |
NCT01020643 -
Closed-loop Sedation of Propofol for Patients Undergoing Spinal Anesthesia
|
Phase 4 | |
Completed |
NCT00318955 -
Post-Marketing Clinical Study to Assess Efficacy and Safety of Dexmedetomidine in Post-Operative Patients
|
Phase 4 | |
Completed |
NCT04621526 -
Monitored Anesthesia Care: Dexmedetomidine-Ketamine Versus Dexmedetomidine- Propofol For Chronic Subdural Hematoma
|
Phase 1/Phase 2 | |
Completed |
NCT01873612 -
Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers
|
Phase 4 | |
Not yet recruiting |
NCT03466242 -
IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures
|
Early Phase 1 | |
Completed |
NCT02679781 -
Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care
|
N/A | |
Completed |
NCT03885427 -
Analgo-Sedative Effects Of Oral, Or Nebulized Ketamine In Pre-schoolers Undergoing Elective Surgery.
|
Early Phase 1 | |
Completed |
NCT00452426 -
Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy
|
Phase 3 | |
Completed |
NCT00261599 -
An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy
|
Phase 3 | |
Completed |
NCT00641563 -
Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)
|
N/A | |
Active, not recruiting |
NCT01118884 -
Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide for Uncooperative Children
|
Phase 3 | |
Terminated |
NCT00809380 -
Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial
|
N/A | |
Completed |
NCT03886454 -
Incidence and Nature of Respiratory Impairment in Consecutive Patients Undergoing Bronchoscopy Under Conscious Sedation: A Pilot Study
|
||
Completed |
NCT03925779 -
Conscious Sedation for Outpatient Colonoscopy
|
Phase 2 | |
Completed |
NCT06181188 -
Use of Ketamine for Conscious Sedation in Flexible Bronchoscopy
|
Phase 4 |